芪参益气滴丸联合非洛地平治疗冠心病心绞痛的临床研究

目的 探讨芪参益气滴丸联合非洛地平缓释片治疗冠心病心绞痛的临床疗效。方法 选取2022年6月—2023年6月皖南医学院第二附属医院收治的冠心病心绞痛患者90例，依据用药情况分为对照组（45例）和治疗组（45例）。对照组患者口服非洛地平缓释片，5 mg/次，1次/d。在对照组的基础上，治疗组口服芪参益气滴丸，1袋/次，3次/d。两组治疗14 d。观察两组患者临床疗效，比较治疗前后两组患者症状好转时间，及磷酸肌酸酶同工酶（CK-MB）、磷酸肌酸激酶（CK）、乳酸脱氢酶（LDH）水平，6 min步行距离试验量表（6MWT）、精神状态评价量表（MMSE）和全球急性冠状动脉事件注册（GRACE）评分。结果 治疗后，治疗组总有效率为93.33%，明显高于对照组（80.00%，P＜0.05）。治疗后，治疗组症状好转时间均明显早于对照组（P＜0.05）。治疗后，两组患者心肌酶中CK-MB、CK和LDH水平比治疗前明显降低（P＜0.05），且治疗组明显低于对照组（P＜0.05）。治疗后，两组患者6MWT和MMSE评分明显升高，而GRACE评分明显降低（P＜0.05），且治疗组6MWT、MMSE评分和GRACE评分明显好于对照组（P＜0.05）。结论 芪参益气滴丸与非洛地平缓释片协同治疗，能较好的对心绞痛症状明显改善，心肌供血能力增强，且有效改善运动耐受力、精神状态，降低预后风险。

Clinical study on Qishen Yiqi Dropping Pills combined with felodipine in treatment of heart disease and angina pectoris

Objective To explore the clinical s efficacy of Qishen Yiqi Dropping Pills combined with felodipine in treatment of heart disease and angina pectoris. Methods Patients (90 cases) with heart disease and angina pectoris in the second affiliated Hospital of Wannan Medical College from June 2022 to June 2023 were divided into control (45 cases) and treatment (45 cases) group according to drug use. Patients in the control group were po administered with Felodipine Sustained Release Tablets, 5 mg/time, once daily. Patients in the treatment group were po administered with Qishen Yiqi Dropping Pills on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical evaluations were evaluated, the symptom relief time, CK-MB, CK, LDH, 6MWD, MMSE and GRACE in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 93.33%, which was significantly higher than that of the control group (80.00%, P < 0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the levels of CK-MB, CK, and LDH in myocardial enzymes in two groups were significantly lower than those before treatment (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the 6MWD test and MMSE score were significantly increased, while the GRACE score was significantly decreased in two groups (P < 0.05), and the 6MWD test, MMSE score and GRACE score in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion The synergistic treatment of Qishen Yiqi Dropping Pills and felodipine can significantly improve the symptoms of angina pectoris, enhance myocardial blood supply, effectively improve exercise tolerance, mental state, and reduce the risk of prognosis.